Faculty Profiles - NASU Yasutomo

Papers - NASU Yasutomo

Division display 461 - 480 of about 612 ／ All the affair displays >>

Telomerase-specific replication-selective virotherapy for prostate cancer Reviewed

Kaku Haruki, Nasu Yasutomo, Huang Peng, Saika Takashi, Kagawa Shunsuke, Fujiwara Toshiyoshi, Kumon Hiromi, Urata Yasuo

JOURNAL OF GENE MEDICINE 8 ( 12 ) 1454 2006.12

無阻血と阻血による体腔鏡下腎部分切除術の周術期成績の比較検討

小林泰之, 真鍋大輔, 江原伸, 雑賀隆史, 那須保友, 公文裕巳

日本内視鏡外科学会雑誌 11 ( 7 ) 424 - 424 2006.12

尿路性器癌におけるHybrid Surgery 良い視野、少ない出血、確実なcancer control

雑賀隆史, 小林泰之, 真鍋大輔, 江原伸, 上原慎也, 那須保友, 公文裕巳

Japanese Journal of Endourology and ESWL 19 ( 3 ) 249 - 249 2006.10

前立腺癌におけるHybrid radical prostatectomy 良い視野、少ない出血、確実なcancer control

雑賀隆史, 小林泰之, 真鍋大輔, 江原伸, 上原慎也, 渡邊豊彦, 那須保友, 公文裕巳

西日本泌尿器科 68 ( 増刊 ) 124 - 124 2006.10

ゾレドロン酸使用と関連したCRP上昇

甲斐誠二, 雑賀隆史, 上原慎也, 松本裕子, 平田武志, 小林泰之, 石井亜矢乃, 石井和史, 江原伸, 那須保友, 公文裕巳

西日本泌尿器科 68 ( 増刊 ) 197 - 197 2006.10

密封小線源療法を施行された前立腺癌患者のQOLに関する研究恥骨後式根治的前立腺摘除術とのProspectiveな比較において

雑賀隆史, 中西代志子, 江原伸, 真鍋大輔, 谷本竜太, 枝村康平, 小林知子, 賀来春紀, 津島知靖, 那須保友, 公文裕巳

日本癌治療学会誌 41 ( 2 ) 581 - 581 2006.9

進行性尿路上皮癌に対するGemcitabine(GEM)、Cisplatin(CDDP)、Paclitaxel(PAC)-GCP療法-の検討

谷本竜太, 眞鍋大輔, 和田耕一郎, 枝村康平, 小林知子, 江原伸, 賀来春紀, 雑賀隆史, 那須保友, 公文裕巳

日本癌治療学会誌 41 ( 2 ) 596 - 596 2006.9

腎癌術後に発症した単発性骨転移に対し椎体置換術を施行した3例

枝村康平, 雑賀隆史, 田中雅人, 谷本竜太, 小林知子, 真鍋大輔, 江原伸, 賀来春紀, 那須保友, 津島知靖, 尾崎敏文, 公文裕巳

腎癌研究会会報 ( 31 ) 11 - 12 2006.9

125Iシード線源による前立腺癌永久挿入密封小線源治療

江原伸, 真鍋大輔, 枝村康平, 谷本竜太, 小林知子, 雑賀隆史, 那須保友, 公文裕巳

日本癌治療学会誌 41 ( 2 ) 574 - 574 2006.9

Phase I/II Study of Adenoviral Vector Delivery of HSV-tk Gene and the Intravenous Administration of Ganciclovir in Men with Local Recurrence of Prostate Cancer after Hormonal Therapy Reviewed

Nasu Yasutomo, Kaku Haruki, Ebara Shin, Saika Takashi, Kumon Hiromi, Thompson Timothy C

MOLECULAR THERAPY 13 S19 - S20 2006.5

Effects of radiofrequency ablation on individual renal function: Assessment by technetium-99m mercaptoacetyltriglycine renal scintigraphy Reviewed

T Mukai, S Sato, T Iguchi, H Mimura, K Yasui, H Gobara, T Saika, Y Nasu, H Kumon, S Kanazawa

ACTA MEDICA OKAYAMA 60 ( 2 ) 85 - 91 2006.4

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

We quantitatively evaluated total and individual renal function by technetium-99m mercaptoacetyltriglycine (Tc-99m MAG3) renal scintigraphy before and after radiofrequency ablation (RFA) of renal tumors. Eleven patients who underwent Tc-99m MAG3 renal scintigraphy I week before and after RFA were evaluated (7 men and 4 women; age range: 23-83 years; mean age: 60.6 years). Five patients had solitary kidneys, and five had normally or minimally functioning contralateral kidneys. One patient had a renal cell carcinoma in the contralateral. kidney. One patient with a solitary kidney underwent RFA a second time for a residual tumor. In patients with a solitary kidney, MAG3 clearance decreased after 5 of 6 RFAs, and in patients with a normally functioning contralateral kidney, MAG3 clearance decreased after 4 of 5 RFAs, but no significant differences were observed between before and after treatments. In addition to the total MAG3 clearance, the split MAG3 clearance was evaluated in patients with a normally functioning contralateral. kidney. MAG3 clearance decreased in 4 of 5 treated kidneys, while it adversely increased in the contralateral kidneys after 4 of 5 RFAs. No significant differences, however, were observed between before and after treatments. The results of our study revealed no significant differences in sCr, BUN, CCr, or MAG3 clearance between pre- and post-RFA values. These results support data regarding the functional impact and safety of renal RFA in published reports. We evaluated total and individual renal function quantitatively using Tc-99m MAG3 renal scintigraphy before and after treatment. This scintigraphy was very useful in assessing the effects of RFA on renal function.

Web of Science

researchmap

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Reviewed

H Kaku, T Saika, T Tsushima, S Ebara, T Senoh, T Yamato, Y Nasu, H Kumon

PROSTATE 66 ( 4 ) 439 - 444 2006.3

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY-LISS

INTRODUCTION. In order to elucidate the influence of hormone-releasing hormone (LHRH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long-term LH-RH 10 agonist therapy.
PATIENTS AND METHODS. A consecutive 32 patients who had received LH-RH agonist therapy over 24 months were enrolled. As a baseline, T and LH were measured at the time of LHRH agonist therapy cessation, monthly for 3 months, and subsequently, every 3 months.
RESULTS. The median duration of LH-RH agonist therapy was 30 months (24-87 months) with median follow-up duration of 24 months following cessation. All patients had castrated T levels and suppressed LH levels at baseline. Median duration of castrated T levels following cessation was 6 months. Median time to normalization of T levels was 24 months. LH levels returned to normal within 3 months in all cases. Patients who received androgen deprivation therapy for 30 months or longer required a longer time for recovery of T levels. Patients over 65 years of age showed a statistically significant longer time for recovery of T levels (P = 0.0167).
CONCLUSIONS. Long-term LH-RH agonist therapy has remarkable effects on serum T level that last for a significant time after cessation, a fact that should be applied to the interpretation of both PSA and serum T levels after cessation of androgen deprivation therapy.

DOI： 10.1002/pros.20341

Web of Science

researchmap

Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer Reviewed

H Kaku, T Saika, T Tsushima, A Nagai, T Yokoyama, F Abarzua, S Ebara, D Manabe, Y Nasu, H Kumon

ACTA MEDICA OKAYAMA 60 ( 1 ) 43 - 49 2006.2

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

We evaluated the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cisplatin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no effective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m(2) IFM on days 1 to 5 and 70 mg/m(2) CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50% reduction in prostate-specific antigen was observed in 9 of 18 patients (50% and a more than 50% reduction in bi-dimensionally measurable soft-tissue lesions was observed in 2 of 7 patients (29%). The median duration of response among the cases showing partial response was 40 weeks, while the median duration of response of overall partial-response plus stable cases was 30 weeks. The median survival duration of all cases was 47 weeks. Toxicity was modest and acceptable. In conclusion, the ECT, IFM and CDDP combination chemotherapy regimen is a viable treatment option for HRPC. However, in comparison with our previous chemotherapy regimen of IFM and CDDP, no additional long-lasting effects resulting from the inclusion of ECT could be affirmed.

Web of Science

researchmap

Retroperitoneal neurogenic tumors mimicking lymph node metastasis of malignant disease: A report of two cases

Shinsuke Gohara, Tomoko Kobayashi, Kyouhei Kurose, Shin-Ya Uehara, Haruki Kaku, Takashi Saika, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

Nishinihon Journal of Urology 68 ( 2 ) 55 - 59 2006.2

Language：Japanese Publishing type：Research paper (scientific journal)

We experienced two cases of neurogenic tumor arising from the retroperitoneal space during the clinical course of malignant disease (Case 1: testicular cancer, Case 2: kidney cancer) These retroperitoneal tumors mimicked lymph node metastasis from each of the malignant diseases and a definitive preoperative diagnosis was not made. Tumors were removed under the diagnosis of lymph node metastasis. Postoperative histological analysis revealed neurogenic tumor (Case 1: ganglioneuroma, Case 2: paraganglioma). The postoperative clinical course was uneventful without any additional treatments. Retroperitoneal neurogenic tumor found during the clinical course of active malignant disease can not be differentiated from its metastatic lesion. Preoperative needle biopsy is still controversial. Further development of functional imaging analysis may solve this clinical problem.

Scopus

researchmap

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.

Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T

Int J Urol 13 ( 7 ) 932 - 938 2006

The Jounal of gene medicine Japanese society of gene therapy young investigator award 2006

Nasu Y

The Journal of Gene Medicine 8 1363 - 1364 2006

Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

Nakamura K, Nasu Y, Hongo A, Matsuo T, Kodama J, Ebara S, Nagai A, Abrzua F, Kumon H, Hiramatsu Y

International Journal of Oncology 28 393 - 398 2006

Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA

Yamato K, Fen J, Kobuchi H, Nasu Y, Yamada T, Nishihara T, Ikeda Y, Kizaki M, Yoshinouchi M

Cancer Gene Therapy 13 234 - 241 2006

OP-114 性状未確定のリンパ節病変に対する鏡視下リンパ節摘除の有用性(一般演題口演,第94回日本泌尿器科学会総会)

村田匡, 雑賀隆史, 上原慎也, 江原伸, 真鍋大輔, 永井敦, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 309 - 309 2006

MP-650 体腔鏡下腎尿管全摘除術が施行された上部尿路癌の長期成績について : 開放手術との比較において(一般演題ポスター,第94回日本泌尿器科学会総会)

真鍋大輔, 雑賀隆史, 江原伸, 上原慎也, 谷本竜太, 賀来春紀, 藤田竜二, 入江伸, 野崎邦浩, 津島知靖, 永井敦, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 97 ( 2 ) 529 - 529 2006

　 PREV - NEXT 　

< NASU Yasutomo >

Papers - NASU Yasutomo